Advanced search
Publication Cover
Current Medical Research and Opinion Volume 21, 2005 - Issue 12
Submit an article Journal homepage
188
Views
13
CrossRef citations to date
0
Altmetric
Original Article

Cost-minimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension

L. Narine PharmIdeas USA Inc., Charlotte, NC, USA; University of North Carolina at Charlotte, College of Health and Human Services, Charlotte, NC, USA
,
L. K. Hague University Hospitals of Cleveland, Cleveland, OH, USA
,
J. H. Walker PharmIdeas Research & Consulting Inc., Oakville, ON, Canada; Brock University, Faculty of Business, St. Catharines, ON, Canada
,
C. Vicente PharmIdeas Research & Consulting Inc., Oakville, ON, Canada
,
R. Schilz Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, USA
,
O. Desjardins PharmIdeas Research & Consulting Inc., Oakville, ON, Canada
,
T. R. Einarson PharmIdeas Research & Consulting Inc., Oakville, ON, Canada; University of Toronto, Faculty of Pharmacy, Toronto, ON, Canada
&
M. Iskedjian PharmIdeas USA Inc., Charlotte, NC, USA; PharmIdeas Research & Consulting Inc., Oakville, ON, CanadaCorrespondence[email protected]
 show all
Pages 2007-2016 | Accepted 21 Oct 2005, Published online: 07 Nov 2005

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Wouter Jacobs & Anton Vonk-Noordegraaf. (2009) Epoprostenol in pulmonary arterial hypertension. Expert Opinion on Drug Metabolism & Toxicology 5:1, pages 83-90.
Read now

Articles from other publishers (12)

Antony Sameh Mansour. (2023) Autoregulation: mediators and renin–angiotensin system in diseases and treatments. Future Journal of Pharmaceutical Sciences 9:1.
Crossref
Stephen A. Hart, Gaurav Arora & Brian Feingold. (2018) Resource utilization at the time of prostacyclin initiation in children in pulmonary arterial hypertension: a multicenter analysis. Pulmonary Circulation 8:1, pages 1-7.
Crossref
Shuyan Gu, Huimei Hu & Hengjin Dong. (2015) Systematic Review of the Economic Burden of Pulmonary Arterial Hypertension. PharmacoEconomics 34:6, pages 533-550.
Crossref
David B. Frank, Matthew A. Crystal, David L. S. Morales, Ken Gerald, Brian D. Hanna, George B. MalloryJr.Jr. & Joseph W. Rossano. (2015) Trends in Pediatric Pulmonary Hypertension–Related Hospitalizations in the United States from 2000–2009. Pulmonary Circulation 5:2, pages 339-348.
Crossref
Nika Skoro-Sajer. (2012) Optimal Use of Treprostinil in Pulmonary Arterial Hypertension. Drugs 72:18, pages 2351-2363.
Crossref
Antonio Roman, Joan A. Barberà, Pilar Escribano, Maria L. Sala, Laia Febrer, Itziar Oyagüez, Eliazar Sabater & Miguel Á. Casado. (2012) Cost Effectiveness of Prostacyclins in Pulmonary Arterial Hypertension. Applied Health Economics and Health Policy 10:3, pages 175-188.
Crossref
Kamal K. Mubarak. (2010) A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respiratory Medicine 104:1, pages 9-21.
Crossref
Matthew Thomas. 2010. Membrane Receptors, Channels and Transporters in Pulmonary Circulation. Membrane Receptors, Channels and Transporters in Pulmonary Circulation 475 490 .
Margaret C. Garin, Leslie Clark, Elinor C.G. Chumney, Kit N. Simpson & Kristin B. Highland. (2009) Cost-Utility of Treatments for Pulmonary Arterial Hypertension. Clinical Drug Investigation 29:10, pages 635-646.
Crossref
Ronald J. Oudiz & Harrison W. Farber. (2009) Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: An experience-based review. American Heart Journal 157:4, pages 625-635.
Crossref
Oren K. Fix, Nathan M. Bass, Teresa De Marco & Raphael B. Merriman. (2007) Long-term follow-up of portopulmonary hypertension: Effect of treatment with epoprostenol. Liver Transplantation 13:6, pages 875-885.
Crossref
Adrian Hendrickse, Fareed Azam & M. Susan Mandel. (2007) Hepatopulmonary syndrome and portopulmonary hypertension. Current Treatment Options in Cardiovascular Medicine 9:2, pages 127-136.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.